Newsletter

Stay up to date on all things atrial fibrillation. Sign up and we’ll send you the latest news, resources, scientific breakthroughs, events, tips, and much more.

Share this post on your profile with a comment of your own:

Successfully Shared!

View on my Profile

Liraglutide Effect in Atrial Fibrillation

January 24, 2020

Overview

The goal of this study is to use a medication called Liraglutide to reduce fat deposits surrounding the heart, and to possibly reduce atrial fibrillation activity. Patients will take the medication and participate in a weight management and exercise program for 30 minutes, 2 to 4 times a week. Patients will also undergo lifestyle changes if necessary, including hyperlipidemia management, management of obstructive sleep apnea, management of hypertension, diabetes management, smoking cessation, and alcohol abstinence or reduction.

 

Study Information

60 subjects will be enrolled in the study. The primary purpose of the trial is treatment. The study began on March 18, 2018 and is estimated to be completed by December 31, 2022.

 

Inclusion Criteria

 

  • Male and female, age 18 or older
  • Persistent atrial fibrillation defined as continuous AF that is sustained beyond 7 days (or atrial fibrillation in which a decision is made to cardiovert the patient prior to 7 days).
  • BMI ≥27 kg/m2
  • Patient wishes to undergo catheter ablation procedure for treatment of atrial fibrillation
  • Receiving follow-up care at the University of Miami

 

Exclusion Criteria

 

  • Inability to sign informed consent
  • Patients with paroxysmal atrial fibrillation and longstanding persistent atrial fibrillation
  • Prior ablation for atrial fibrillation
  • Patients not appropriate candidates for catheter ablation such as those with AF due to acute or chronic precipitating medical conditions, for example hypothyroidism and hyperthyroidism, significant pulmonary disease, pulmonary embolism, left atrial thrombus, class IV heart failure)
  • Patients with a life expectancy <1 year
  • Patients with a serious medical condition (for example, recent cancer with chemotherapy or radiation therapy within 4 weeks prior to entering the study) who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
  • Known contraindications to Liraglutide, such as previous history of pancreatitis or medullary thyroid carcinoma
  • Personal or family history of multiple endocrine neoplasia
  • Known serious hypersensitivity reaction to Liraglutide
  • Patients using insulin, sulfonylureas, glitazones, sodium-glucose transporters 2 inhibitors (SGLT2i), other Glucagon-like peptide analogues or dipeptidyl peptidase 4 inhibitors
  • Type 1 diabetes, defined by American Diabetes Association criteria, history of diabetic ketoacidosis, pancreas or beta-cell transplantation, or diabetes due to pancreatitis or pancreatectomy
  • Pregnant women
  • Women who are breast-feeding or intend to become pregnant

 

Location

The study will take place at the University of Miami, Miami, Florida, United States, 33136. If you have any questions, please contact Carmen Baez-Garcia, RN at 305-243-3845 / cbaezgarcia@med.miami.edu or Barbara Lang, RN at 305-243-3845 / blang@med.miami.edu.

 

Sponsors / Collaborators

The study is sponsored by the University of Miami. The principal investigator is Jeffery Goldberger, MD of the University of Miami.

View All Clinical Trials

Clinical Trials

Understanding and Improving Anticoagulation Dosing for Patients With Atrial Fibrillation

This study aims to survey patients with atrial fibrillation in order to understand direct-acting oral anticoagulant (DOAC) treatment from the…

iCLAS for Persistent Atrial Fibrillation

This study aims to evaluate the safety of the Adagio AF Cryoablation System (iCLAS™) for ablation treatment of persistent atrial fibrillation.…

Esophageal Deviation in Atrial Fibrillation Ablation

Ablation treatment in the posterior wall of the left atrium can cause thermal injury to the esophagus, which is a very common occurrence. The goal…

Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter

The goal of this study is to compare heart rate control (heart rate <110 beats per minute) at 2 hours after taking the medication diltiazem…

Low Voltage-Directed Catheter Ablation for Atrial Fibrillation

The goal of this study is to determine the long term success of non-paroxysmal ablation to treat atrial fibrillation using three different…

The Genetic Basis for Atrial Fibrillation

Veteran patients with atrial fibrillation will be examined for common genetic polymorphisms, and identify…

Mapping Electrogram Morphology Recurrence for Atrial Fibrillation Ablation

The goal of this study is to see how electrogram morphology recurrence (EMR) mapping works on patients with atrial…

High-resolution MRI of Atrial Fibrillation Patients Prior to Focal Impulse and Rotor Modulation (FIRM) Ablation

The goal of the study is to find a correlation between FIRM targeted sites and micro-anatomic fibrotic tracks. Patients will first undergo a…

Send this to a friend